Method for determining metabolites in eight-component kidney-tonifying capsules

Through the UPLC-Q-TOF-MS detection method, the problem of difficult to determine the metabolites in Bazi Bushen Capsules in Chinese medicine quality control was solved, and the characterization of 42 exogenous substances was achieved, which improved the accuracy and reliability of Chinese medicine quality control. sex.

CN119086760APending Publication Date: 2024-12-06SHIJIAZHUANG YILING PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411263441.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

At this stage, in the quality control of traditional Chinese medicine, especially the complexity of chemical composition and in vivo metabolic changes of Bazi Bushen Capsules, the quality markers are difficult to determine, hindering the development of its quality control research.

Method used

UPLC-Q-TOF-MS detection method was used to characterize 42 exogenous substances (26 prototypes and 16 metabolites) in the plasma of Bazi Bushen Capsules, and their metabolites in vivo were determined through chromatography and mass spectrometry analysis.

Benefits of technology

Qualitative analysis of metabolites in Bazi Bushen Capsules has been achieved, providing a basis for its quality control and anti-osteoporosis biological activity evaluation, and improving the level of quality control of traditional Chinese medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005036462160000081
    Figure BDA0005036462160000081
  • Figure BDA0005036462160000091
    Figure BDA0005036462160000091
  • Figure BDA0005036462160000101
    Figure BDA0005036462160000101
Patent Text Reader

Abstract

The invention relates to the field of traditional Chinese medicine detection, in particular to a method for determining metabolites in eight-component kidney-tonifying capsules. According to the invention, through UPLC-Q-TOF-MS (Ultra Performance Liquid Chromatography-Quantitative Time-of-Flight Mass Spectrometry) detection, 42 kinds of exogenous substances (26 kinds of prototypes and 16 kinds of metabolites) in the plasma of the eight-component kidney-tonifying capsule are characterized. According to the detection method provided by the invention, qualitative analysis can be carried out on the 42 exogenous substances in the plasma of the eight-seed kidney-tonifying capsules, a basis is provided for in-vivo metabolism research of the eight-seed kidney-tonifying capsules, and the detection method has guiding significance for subsequent research on content determination of components of the eight-seed kidney-tonifying capsules and anti-osteoporosis biological activity evaluation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of traditional Chinese medicine detection, and in particular to a method for determining in vivo metabolites of Bazi Bushen Capsule. Background Art

[0002] Traditional Chinese medicine plays an important role in the prevention and treatment of diseases, and therefore has received increasing attention and recognition worldwide. The quality of traditional Chinese medicine directly affects the clinical efficacy and restricts the development of the modernization of traditional Chinese medicine. However, the complexity of chemical composition and the ambiguity of pharmacological substances are huge obstacles to the quality control of traditional Chinese medicine. In the process of strategy exploration, Liu et al. proposed the concept of quality markers. This concept focuses on the measurability, specificity, transferability, effectiveness and traceability of quality markers of traditional Chinese medicine. The characterization of quality markers involves the integration of multiple properties, including component analysis, content determination, pharmacokinetics, network pharmacology, etc. There are a variety of plant secondary metabolites in traditional Chinese medicine, and components with different structures may have different biological activities. Therefore, the quality markers of traditional Chinese medicine need to consider the different structural types of different components, which is of great significance for the quality control of traditional Chinese medicine based on traditional efficacy. In addition, network pharmacology is increasingly being used to reveal the mechanism of action between active ingredients and disease therapeutic targets. At present, the use of network pharmacology to screen quality markers is mainly based on the degree of association between a single compound and a disease target, and the mode of action of multiple components of traditional Chinese medicine in the form of a combination to cover multiple targets to exert pharmacological effects is not prominent. In addition, the metabolism of TCM ingredients in the body will lead to changes in their biological activity, and the in vivo process of TCM ingredients is also particularly important for determining the quality markers of TCM. It is well known that TCM prescriptions have the characteristics of multi-component, multi-target, and overall regulation, but there are currently few reports on mining TCM quality markers from a holistic perspective. Therefore, this study proposed a digital and holistic strategy to mine the quality markers of absorbable ingredients in Bazi Bushen Capsule in the form of different compositions to reflect the structural diversity and diversity of biological pathways.

[0003] Bazi Bushen Capsule (BZBS) is a traditional Chinese medicine compound, which is composed of 16 single herbs, including Cuscuta, Lycium, Schisandra, Cnidium, Rosa Laevigata, Rubus, Toosendan, Allium, Epimedium, Morinda, Cistanche, Rehmannia, Cyathula, Ginseng, Pilose Antler, and Hippocampus. It is clinically used to prevent and treat symptoms such as soreness of waist and knees, dizziness, tinnitus, and fatigue caused by insufficient kidney yang. Recent pharmacological studies have shown that Bazi Bushen Capsule can significantly improve the bone morphology of aged mice induced by D-galactose and NaNO2, and increase the mineral content in their bone tissue. In addition, Bazi Bushen Capsule can also improve the bone microstructure of the distal tibia in ovariectomized osteoporosis rats. A large number of literature reports show that a variety of single herbs in Bazi Bushen Capsule, such as Cuscuta, Lycium barbarum, Cnidium monnieri, Epimedium, Ginseng, Cistanche deserticola and Rehmannia root, can improve the bone microstructure parameters of ovariectomized osteoporosis model rats / mice. In summary, Bazi Bushen Capsule has a significant anti-osteoporosis effect. Bazi Bushen Capsule has a definite efficacy, but the quality control research of Bazi Bushen Capsule is seriously insufficient. Therefore, it is urgent to find the quality markers of Bazi Bushen Capsule to improve its quality control level.

[0004] It is worth noting that Bazibushen Capsule is a complex system composed of 16 single herbs. Its chemical composition, in vivo metabolism, content determination, anti-osteoporosis biological activity evaluation, etc. have not been reported, which seriously hinders the quality control research of Bazibushen Capsule. Summary of the invention

[0005] In view of this, the present invention provides a method for determining the metabolites of Bazi Bushen Capsule in vivo. The present invention characterized 42 xenobiotics (26 prototypes and 16 metabolites) in Bazi Bushen Capsule plasma by UPLC-Q-TOF-MS detection.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a method for determining the metabolites of Bazi Bushen Capsule in vivo, comprising the following steps:

[0008] The plasma of animals after taking Bazi Bushen Capsule was taken to prepare the sample solution;

[0009] Take the standard sample to prepare the standard solution;

[0010] The sample solution and the standard solution were respectively taken for UPLC-Q-TOF-MS detection to determine the in vivo metabolites of the Bazi Bushen Capsule.

[0011] In some specific embodiments of the present invention, the detection comprises chromatography and mass spectrometry;

[0012] The mobile phase of the chromatographic analysis includes: A is a 0.1% (v / v) formic acid solution, and B is a 0.1% (v / v) formic acid acetonitrile solution.

[0013] In some specific embodiments of the present invention, the flow rate of the chromatography analysis is 0.4 ml / min; and / or the injection volume of the chromatography analysis is 2 μL.

[0014] In some specific embodiments of the present invention, the gradient elution conditions of the chromatographic analysis are: 0-3.5 min, 2%-15% B; 3.5-12.5 min, 15%-36% B; 12.5-19.5 min, 36%-55% B; 19.5-23.5 min, 55%-80% B; 23.5-26 min, 80%-100% B; 26-28 min, 100% B; 28-29 min, 100%-2% B; 29-30 min, 2% B.

[0015] In some specific embodiments of the present invention, the chromatographic analysis uses an ACQUITY UPLC BEHC18 column (2.1 mm×100 mm, 1.7 μm) and the temperature of the chromatographic column is 35°C.

[0016] In some specific embodiments of the present invention, the mass spectrometry analysis uses an electrospray ion source (ESI), positive and negative ion mode detection, the acquisition method is FastDDA, the scanning range is m / z 50-1500Da, the capillary spray voltage ion is 3.0kV (ESI+) and 2.1kV (ESI-), and the cone voltage is 35V.

[0017] In some specific embodiments of the present invention, the source temperature of the mass spectrometry analysis is 140° C., the desolvation gas temperature is 500° C., the desolvation gas flow rate is 1000 L / h, and the cone gas flow rate is 50 L / h.

[0018] In some specific embodiments of the present invention, the low-mass end energy of the dual dynamic collision energy of the mass spectrometry analysis is set to 6-30 eV, and the high-mass end energy is set to 40-90 V; when the TIC intensity rises to above 5000 intensity / second, it automatically switches to MS / MS mode, and switches back to MS patrol scan after five MS / MS scans; the MS and MS / MS patrol scan times are both set to 0.2 seconds.

[0019] In some specific embodiments of the present invention, the sample solution is prepared by: taking plasma after taking the Bazi Bushen Capsule, dissolving it in acetonitrile, vortexing, centrifuging, collecting the supernatant and drying it with nitrogen; using methanol to dissolve the residue again, vortexing, centrifuging, collecting the supernatant, and obtaining the sample solution;

[0020] The preparation method of the standard solution is: dissolving the standard in methanol, centrifuging, filtering, collecting the supernatant, and obtaining the standard solution.

[0021] In some specific embodiments of the present invention, the sample solution is prepared by taking plasma after taking the Bazi Bushen Capsule, dissolving it in acetonitrile, and drying the supernatant with nitrogen; dissolving the residue again with methanol, vortexing, centrifuging at 10°C and 13200rpm for 20 minutes, filtering, and collecting the supernatant.

[0022] The preparation method of the standard solution is as follows: dissolving the standard in methanol, centrifuging at 13200 rpm for 10 minutes, filtering, and collecting the supernatant.

[0023] In some specific embodiments of the present invention, the in vivo metabolites of the Bazi Bushen Capsule include prototype compounds and metabolites;

[0024] The prototype compounds include 13 lignans, 5 coumarins, 3 alkaloids, 1 triterpene, 1 organic acid and 3 other compounds, such as Figure 1 A. Figure 1 B. As shown in Table 1; preferably, the prototype compound includes magnoflorine, cuscutamine, 19α-hydroxyasiatic acid, schisandrin, imperatorin, osthole, isopimpinellin, xanthotoxin, schisantherin A, schisantherin B and schisandrin B;

[0025] The metabolites include 3 prenylated flavonoids, 2 flavonols, 5 coumarins and 6 lignans, e.g. Figure 1 C. Figure 1 D. As shown in Table 2.

[0026] The present invention characterizes 42 exogenous substances (26 prototypes and 16 metabolites) in the plasma of Bazibushen Capsules by UPLC-Q-TOF-MS detection. The detection method provided by the present invention can perform qualitative analysis on 42 exogenous substances (26 prototypes and 16 metabolites) in the plasma of Bazibushen Capsules, providing a basis for the in vivo metabolism study of Bazibushen Capsules, and has guiding significance for the subsequent content determination of Bazibushen Capsules components and the evaluation of anti-osteoporosis biological activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0028] Figure 1 The figures show the extracted ion chromatograms of the prototype (A / B) and metabolites (C / D) in the plasma of rats after oral administration of BZBS; wherein, (A) and (B) show the extracted ion chromatograms of the prototype compound in the plasma of rats after oral administration of BZBS; (C) and (D) show the extracted ion chromatograms of the metabolites in the plasma of rats after oral administration of BZBS. DETAILED DESCRIPTION

[0029] The present invention discloses a method for determining the metabolites in the body of Bazi Bushen Capsule. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0030] The present invention detects 26 prototype compounds and 16 metabolites in total in whole blood of rats after oral administration of Bazi Bushen Capsule based on ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS):

[0031] Chromatographic system: Waters ACQUITY UPLC I-Class Plus system

[0032] Chromatographic column: ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm);

[0033] Column temperature: 35 °C;

[0034] Mobile phase: A is 0.1% (v / v) formic acid solution, B is 0.1% (v / v) formic acid acetonitrile solution;

[0035] Flow rate: 0.4ml / min;

[0036] Injection volume: 2 μL;

[0037] Gradient elution conditions: 0-3.5min, 2%-15% B; 3.5-12.5min, 15%-36% B; 12.5-19.5min, 36%-55% B; 19.5-23.5min, 55%-80% B; 23.5-26min, 80%-100% B; 26-28min, 100% B; 28-29min, 100%-2% B; 29-30min, 2% B;

[0038] Mass spectrometer: Waters Xevo G2-XS QTOF

[0039] Mass spectrometry conditions: electrospray ion source (ESI), positive and negative ion mode detection; acquisition method Fast DDA; scanning range m / z 50-1500Da; capillary spray voltage ion 3.0kV (ESI+) and 2.1kV (ESI-); cone voltage 35V; source temperature 140℃; desolvation gas temperature 500℃; desolvation gas flow rate 1000L / h, cone gas flow rate 50L / h; dual dynamic collision energy low mass end energy set to 6-30eV, high mass end energy set to 40-90V; automatically switch to MS / MS mode when TIC intensity rises to above 5000 intensity / second, and switch back to MS patrol scan after five MS / MS scans; MS and MS / MS patrol scan times are both set to 0.2 seconds.

[0040] Preparation of plasma samples: 2 ml of plasma sample was dissolved in 6 ml of acetonitrile, vortexed, centrifuged at 13200 rpm (10°C) for 10 min, and the supernatant was dried with nitrogen; the residue was redissolved in 200 μL of methanol, vortexed, and centrifuged at 13200 rpm (10°C) for 20 min.

[0041] Materials and methods

[0042] Instruments and reagents:

[0043] Samples were measured on a Waters ACQUITY UPLC I-Class Plus system equipped with an autosampler, online degasser, binary solvent delivery system, and a Waters Xevo G2-XS QTOF with ESI interface.

[0044] Cuscuta, Lycium, Schisandra, Cnidium, Rosa laevigata, Rubus idaeus, Toosendan, Allium, Epimedium, Morinda officinalis, Cistanche, Rehmannia, Cyathula, Ginseng, Pilose antler, Hippocampus and 10 batches of Bazi Bushen Capsules were provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd., China.

[0045] Monotropein, deacetylaspelurosidic acid, rehmannioside D, echinacoside, cyasterone, xanthotoxol, isopimpinellin, xanthotoxin, toosendanin, 19α-hydroxyasiatic acid, rubiadin-1-methylether, schisandrin, schisandrolB, imperatorin, osthole, schisantherin A, schisantherin B, schisandrin A, cuscutamine, schisandrin B, kaempferol3-O-rutinoside, kaempferol, isochlorogenicacid C, and isoquercitrin were purchased from Chengdu Pusi Biotechnology Co., Ltd. Nystose, ginsenoside Rg2, ginsenoside Rc, ginsenoside Rb2, icariin, epimedin A, epimedin B, epimedin C, icariside I, icariside II, icaritin, betaine, magnoflorine, neochlorogenic acid, chlorogenic acid were purchased from Shanghai Ronghe Pharmaceutical Technology Co., Ltd. Hyperin, gallic acid, elagic acid, ginsenoside Rb1, γ-Glctamyl-S-allylcysteine, were purchased from Chengdu Purifa Technology Development Co., Ltd. Ferulic acid, astragalin, azelaic acid, ginsenoside Re, ginsenoside Ro, ginsenoside Rd were purchased from Chengdu Kroma Co., Ltd. Adenine, 6-hydroxypurine were purchased from Shanghai MacLean Biochemical Technology Co., Ltd. Ginsenoside Rg1, quercetin were purchased from Chengdu Efa Biological Co., Ltd. Acteoside was purchased from Anhui Zesheng Technology Co., Ltd. After HPLC identification, the purity of all reference substances was ≥98%.

[0046] Water for mass spectrometry (HPLC grade) was purchased from Beijing Watsons Distilled Water Co., Ltd.; mass spectrometry grade methanol and acetonitrile were purchased from Thermo Fisher Scientific, USA; mass spectrometry grade formic acid was purchased from Sigma Aldrich, USA; other reagents were of analytical grade and purchased from the market.

[0047] The raw materials and reagents used in the method for determining the in vivo metabolites of Bazi Bushen Capsule provided by the present invention can all be purchased from the market.

[0048] The present invention will be further described below in conjunction with embodiments:

[0049] Example 1 Experimental Animals and Dosage of Bazi Kidney-tonifying Drug

[0050] Female Sprague-Dawley rats (220 ± 20 g) were obtained from the Guangdong Experimental Animal Center (Guangzhou). The animal experiment protocol was reviewed and approved by the Experimental Animal Ethics Committee of Jinan University (IACUC-20220625-01). All experimental procedures were in accordance with the Guide for the Care and Use of Laboratory Animals (Jinan University). Rats were housed in an environmentally controlled animal room (22-25 ° C, relative humidity 50-60%, 12-h light-dark cycle) and were given a normal diet for two weeks before the experiment. Bazi Bushen Capsules were dissolved in sterile water and gavaged at a dose of 0.2 g / mL; 8 rats (Bazi Bushen group) were gavaged for 3 consecutive days at a dose of 1 g / kg / day; the remaining 2 rats (blank group) were gavaged with an equal amount of sterile water.

[0051] Example 2 Sample collection and pre-treatment method

[0052] Whole blood samples were collected at 0.5 hours, 1 hour, 2 hours and 4 hours (four time points) after the last administration of the Ba Zi Bu Shen group in Example 1. After the blood samples were centrifuged at 13,200 rpm (10°C) for 10 minutes, the plasma was separated into a clean test tube to obtain the plasma samples of the Ba Zi Bu Shen group, which were stored at -80°C until drug analysis. Blank plasma samples were obtained from blank group rats in the same way.

[0053] Three times the amount of acetonitrile was added to 2 mL of plasma sample, vortexed and centrifuged at 13200 rpm (10°C) for 10 minutes, and the supernatant was blown dry with nitrogen. The residue was redissolved in 200 μL of methanol, vortexed, and then centrifuged at 13200 rpm (10°C) for 20 minutes.

[0054] Example 3 Instrumental Analysis Conditions

[0055] Liquid phase conditions: Chromatographic separation was performed on an ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm), and the column temperature was 35°C. The mobile phase consisted of 0.1% (v / v) formic acid (phase A) and 0.1% (v / v) formic acid in acetonitrile (phase B). Flow rate: 0.4 mL / min; elution gradient: 0-3.5 min, 2%-15% B; 3.5-12.5 min, 15%-36% B; 12.5-19.5 min, 36%-55% B; 19.5-23.5 min, 55%-80% B; 23.5-26 min, 80%-100% B; 26-28 min, 100% B; 28-29 min, 100%-2% B; 29-30 min, 2% B. The injection volume was 2 μL.

[0056] Mass spectrometry conditions: mass range 50-1500Da; capillary voltage 3.0kV (ESI + ) and 2.1kV (ESI-); cone voltage was 35V; ion source temperature was 140℃; desolvation temperature was 500℃; cone backflush gas flow rate was 50L / h; desolvation gas flow rate was 1000L / h; low channel collision energy was 6-30eV, and high channel collision energy was 40-90V; when the TIC intensity exceeded 5000intensity / s, it automatically switched to MS / MS mode and switched back to MS scan after five MS / MS scans; the MS and MS / MS survey scan times were both set to 0.2. In one MS scan, the five ions with the highest response were automatically selected for MS / MS. The mass accuracy was calibrated using a leucine-enkephalin solution internal standard (m / z 556.2771[M+H] in positive ion mode) + , m / z 554.2615 [MH]- in negative ion mode). LockSpray TM The flow rate was 5 μL / min and data were collected using MassLynx 4.2 software (Waters, Milford, MA, USA).

[0057] Example 4 In vivo metabolic experimental results in rat plasma

[0058] According to the analytical method described in Example 3, a total of 26 prototype substances (13 lignans, 5 coumarins, 3 alkaloids, 1 triterpene, 1 organic acid and 3 other substances) were detected in the plasma of rats after oral administration of Bazi Bushen Capsule, of which 11 prototype components such as magnoflorine, cuscutamine, 19α-hydroxyasiatic acid, schisandrin, imperatorin, osthole, isopimpinellin, xanthotoxin, schisantherin A, schisantherin B and schisandrin B were confirmed by comparison with the standard. TM The software processed the data and used the mass defect filter (MDF) to identify the metabolites. The structures of several characteristic components were input into Metabolynx as parent components. TM The software contains metabolites such as icaritin, hyperin, rutin, osthole, xanthotoxin, schisandrin, schisantherin A, monotropein, echinacoside, cuscutamine, cyasterone, ginsenosideRg1 and ginsenoside Rb1. The characteristics of 16 metabolites (3 prenylated flavonoids, 2 flavonols, 5 coumarins and 6 lignans) of rutin, hyperin, icaritin, icariside II, osthole and schisantherin A were preliminarily determined by accurate mass, characteristic ion and neutral loss analysis. The main metabolic pathways are oxidation, demethylation, hydrolysis, sulfation and glucuronidation. The extracted ion chromatograms (EIC) of the prototype and metabolites in the plasma of rats after oral administration of Bazi Bushen Capsule are shown in Figure 1 The UPLC-Q-TOF-MS data of the prototype are shown in Table 1. The UPLC-Q-TOF-MS data of the metabolites are shown in Table 2.

[0059] It is noteworthy that epimedin C, icariin, icariside II, icaritin, rutin, and hyperin were not detected in vivo after oral administration of Bazibushen capsules, but interestingly, their glucuronide metabolites (M1-M5) were detected in plasma. Therefore, magnoflorine, cuscutamine, 19α-hydroxyasiatic acid, imperatorin, osthole, isopimpinellin, xanthotoxin, schisandrin, schisantherin A, schisantherin B, schisandrin B, epimedin C, icariin, icariside II, icaritin, rutin, and hyperin were selected as absorbable candidate components.

[0060] Table 1. Characterization of the prototype of Bazi Bushen Capsule in rat plasma after oral administration

[0061]

[0062]

[0063]

[0064] Table 2. Characteristics of metabolites in rat plasma after oral administration of Bazi Bushen Capsule

[0065]

[0066] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for determining the metabolites of Bazi Bushen Capsule in vivo, characterized in that: The steps include: The plasma of animals after taking Bazi Bushen Capsule was taken to prepare the sample solution; Take the standard sample to prepare the standard solution; The sample solution and the standard solution were respectively taken for UPLC-Q-TOF-MS detection to determine the in vivo metabolites of the Bazi Bushen Capsule.

2. The measuring method according to claim 1, characterized in that The detection includes chromatography and mass spectrometry; The mobile phase of the chromatographic analysis includes: A is a 0.1% (v / v) formic acid solution, and B is a 0.1% (v / v) formic acid acetonitrile solution.

3. The measuring method according to claim 2, characterized in that The flow rate of the chromatographic analysis is 0.4 ml / min; and / or The injection volume of the chromatographic analysis was 2 μL.

4. The assay method according to claim 2 or 3, characterized in that The gradient elution conditions of the chromatographic analysis are: 0-3.5 min, 2%-15% B; 3.5-12.5 min, 15%-36% B; 12.5-19.5 min, 36%-55% B; 19.5-23.5min, 55%-80%B; 23.5-26min, 80%-100%B; 26-28min, 100%B; 28-29min, 100%-2%B; 29-30min, 2%B.

5. The assay method according to any one of claims 2 to 4, characterized in that The chromatographic analysis used an ACQUITY UPLC BEH C18 column, and the temperature of the column was 35°C.

6. The assay method according to any one of claims 2 to 5, characterized in that The mass spectrometry analysis adopts an electrospray ion source, positive ion and negative ion mode detection, the acquisition method is Fast DDA, the scanning range is m / z 50-1500Da, the capillary spray voltage ion is 3.0kV (ESI+) and 2.1kV (ESI-), and the cone voltage is 35V.

7. The detection method according to any one of claims 2 to 6, characterized in that: The source temperature of the mass spectrometry analysis was 140° C., the desolvation gas temperature was 500° C., the desolvation gas flow rate was 1000 L / h, and the cone gas flow rate was 50 L / h.

8. The detection method according to any one of claims 2 to 7, characterized in that: The dual dynamic collision energy of the mass spectrometry analysis is set to 6 to 30 eV at the low mass end and 40 to 90 eV at the high mass end; when the TIC intensity rises to more than 5000 intensity / second, it automatically switches to MS / MS mode, and switches back to MS inspection scanning after five MS / MS scans; The scan time for both MS and MS / MS was set to 0.2 s.

9. The detection method according to any one of claims 1 to 8, characterized in that: The preparation method of the sample solution is as follows: taking the plasma after taking the Bazi Bushen Capsule, dissolving it in acetonitrile, vortexing, centrifuging, collecting the supernatant and drying it with nitrogen; using methanol to dissolve the residue again, vortexing, centrifuging, collecting the supernatant, and obtaining the sample solution; The preparation method of the standard solution is: dissolving the standard in methanol, centrifuging, filtering, collecting the supernatant, and obtaining the standard solution.

10. The detection method according to any one of claims 1 to 9, characterized in that: The in vivo metabolites of the Bazi Bushen Capsule include prototype compounds and metabolites; The prototype compounds include 13 lignans, 5 coumarins, 3 alkaloids, 1 triterpenoid, 1 organic acid and 3 other compounds, as shown in FIG. 1A , FIG. 1B and Table 1 ; magnoflorine, cuscutamine, 19α-hydroxyasiatic acid, imperatorin, osthole, isopimpinellin, xanthotoxin, schisandrin, schisantherin A, schisantherin B, schisandrin B, epimedin C, icariin, icariside II, icaritin, rutin and hyperin; preferably, the prototype compounds include magnoflorine, cuscutamine, 19α-hydroxyasiatic acid, schisandrin, imperatorin, osthole, isopimpinellin, xanthotoxin, schisantherin A, schisantherin B and schisandrin B; The metabolites include 3 prenylated flavonoid compounds, 2 flavonol compounds, 5 coumarins and 6 lignans, as shown in FIG. 1C , FIG. 1D and Table 2 .